Exelixis
EXEL
#1656
Rank
NZ$22.75 B
Marketcap
NZ$90.55
Share price
-1.01%
Change (1 day)
33.37%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2026 (TTM): NZ$1.71 Billion

According to Exelixis's latest financial reports the company's current earnings are NZ$2.37 Billion. In 2025 the company made an earning of NZ$1.64 Billion, an increase over its 2024 earnings that were of NZ$1.18 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$1.71 B4.47%
2025 NZ$1.64 B38.08%
2024 NZ$1.18 B164.69%
2023 NZ$0.44 B9.89%
2022 NZ$0.40 B-20.33%
2021 NZ$0.51 B124.82%
2020 NZ$0.22 B-67.14%
2019 NZ$0.69 B-11.94%
2018 NZ$0.78 B185.09%
2017 NZ$0.27 B-325.82%
2016 -NZ$0.13 Billion-58.12%
2015 -NZ$0.3 Billion-37.61%
2014 -NZ$0.47 Billion9.75%
2013 -NZ$0.43 Billion65.96%
2012 -NZ$0.26 Billion-291.63%
2011 NZ$0.13 B-195.59%
2010 -NZ$0.15 Billion-42.17%
2009 -NZ$0.25 Billion-18.98%
2008 -NZ$0.3 Billion-6.99%
2007 -NZ$0.33 Billion46.3%
2006 -NZ$0.23 Billion33.25%
2005 -NZ$0.17 Billion-30.92%
2004 -NZ$0.24 Billion44.29%
2003 -NZ$0.17 Billion12.86%
2002 -NZ$0.15 Billion22.79%
2001 -NZ$0.12 Billion60.14%
2000 -NZ$74.77 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
NZ$45.31 B 2,489.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$18.47 B 955.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$15.85 B 805.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$13.35 B 663.41%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$22.94 B 1,211.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$16.74 B 856.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
NZ$17.46 B 897.95%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-NZ$56.8 Million-103.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-NZ$50.66 Million-102.89%๐Ÿ‡บ๐Ÿ‡ธ USA